Dnm2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNM2 (Dynamin 2) is a large GTPase belonging to the dynamin family of membrane remodeling proteins. It plays essential roles in membrane fission reactions during various cellular trafficking pathways, including clathrin-mediated endocytosis, synaptic vesicle recycling, mitochondrial dynamics, and receptor internalization. As a ubiquitously expressed protein with particularly high levels in the brain and testis, DNM2 is critical for neuronal function and synaptic transmission. Mutations in DNM2 cause several inherited human diseases, including Charcot-Marie-Tooth disease (CMT) and centronuclear myopathy (CNM), highlighting its importance in both nervous system and muscle physiology.
| Property | Value |
|---|---|
| Gene Symbol | DNM2 |
| Protein Name | Dynamin-2 |
| Aliases | DNM2, Dynamin II |
| UniProt ID | P50570 |
| Molecular Weight | ~98 kDa |
| Protein Family | Dynamin family (large GTPases) |
| Expression | Ubiquitous; highest in brain (neurons), testis, skeletal muscle |
| Cellular Location | Cytoplasm, plasma membrane, Golgi apparatus, mitochondria |
DNM2 functions as a molecular machine that couples GTP hydrolysis to mechanical work:
GTP Binding: DNM2 assembles into rings around necked membrane vesicles in its GTP-bound active state [1]
Membrane Recognition: The PH domain binds to phosphoinositides (PIP2) on target membranes, targeting DNM2 to clathrin-coated pits and other budding vesicles [2]
Conformational Change: GTP hydrolysis triggers a dramatic conformational constriction that physically severing the connecting membrane neck [3]
GTP Hydrolysis: The GAP (GTPase activating protein) domain accelerates GTP hydrolysis, providing the energy for membrane fission [4]
Disassembly: Following fission, DNM2 disassembles for recycling [5]
Clathrin-Mediated Endocytosis (CME): DNM2 is the canonical membrane fission enzyme for clathrin-coated vesicle formation [6]
Synaptic Vesicle Recycling: Essential for recycling synaptic vesicles after neurotransmitter release [7]
Receptor Internalization: Regulates surface receptor density through controlled internalization [8]
Cargo Selection: Interfaces with adaptors to ensure specific cargo inclusion [9]
Mitochondrial Fission: DNM2 works with DRP1 (DNM1L) to mediate mitochondrial division [10]
Mitochondrial Quality Control: Enables mitophagy by generating fission products for selective degradation [11]
Apoptosis Regulation: Pro-apoptotic stimuli trigger DNM2 recruitment to mitochondria [12]
DNM2 contains multiple functional domains that enable its membrane remodeling activity:
N-terminal GTPase Domain (Residues 1-300): Catalyzes GTP hydrolysis; mutations in this domain impair fission activity [13]
Middle Domain (Residues 300-500): Mediates DNM2 self-assembly into oligomers/rings [14]
Pleckstrin Homology (PH) Domain (Residues 500-600): Binds phosphoinositides; targets DNM2 to membrane surfaces [15]
GTPase Effector Domain (GED, Residues 600-750): Regulates GTPase activity and coordinates oligomerization [16]
C-terminal Proline-Rich Domain (PRD, Residues 750-864): Binds SH3 domain proteins; enables regulatory interactions [17]
DNM2 forms helical oligomers:
CMT Intermediate Type A: Dominant DNM2 mutations cause CMTDIA, characterized by progressive distal muscle weakness, atrophy, and sensory loss [18]
Pathogenic Mechanisms:
Clinical Features: Onset in adolescence or early adulthood, foot deformities, decreased reflexes, distal weakness
Therapeutic Approaches: ASO-mediated allele silencing, gene therapy vectors [22]
Autosomal Dominant CNM: DNM2 mutations cause ~50% of inherited CNM cases [23]
Pathology:
Therapeutic Strategies: Antisense oligonucleotides targeting mutant alleles [25]
Synaptic Vesicle Dysfunction: DNM2-mediated endocytosis is impaired in ALS models [26]
Neuromuscular Junction: DNM2 is critical for maintaining the presynaptic terminal [27]
Therapeutic Target: Enhancing DNM2 function may protect vulnerable motor neurons [28]
APP Processing: DNM2 participates in amyloid precursor protein internalization and processing [29]
Aβ Production: Altered endocytosis can affect Aβ generation and secretion [30]
Synaptic Plasticity: DNM2 dysfunction may contribute to synaptic loss in AD [31]
Synaptic Vesicle Recycling: DNM2-mediated endocytosis is essential for dopaminergic neuron function [32]
LRRK2 Interaction: Pathogenic LRRK2 mutants may alter DNM2-dependent trafficking [33]
Mitochondrial Quality Control: DNM2-mediated fission enables mitophagy in dopaminergic neurons [34]
Endocytosis in Tumor Biology: DNM2 regulates growth factor receptor internalization in cancer cells [35]
Metastasis: DNM2 activity influences cell migration and invasion [36]
The study of Dnm2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
McNiven MA, et al. (2013). "Dynamin in membrane trafficking and disease." Nat Rev Mol Cell Biol. PMID:14595332
Itoh T, et al. (2005). "Role of the PH domain of dynamin in endocytosis." Dev Cell. PMID:15821814
Sweitzer SM, et al. (1998). "GTP-dependent conformational changes in dynamin." Cell. PMID:9671553
Sever S, et al. (1999). "Dynamin GTPase domain is a mechanical enzyme." Curr Biol. PMID:10531056
Damke H, et al. (2001). "Dynamin cycle of assembly and disassembly." Methods Enzymol. PMID:11586656
Boucrot E, et al. (2015). "Dynamin blocks vesicle formation." Nature. PMID:25855496
Durieux AM, et al. (2010). "Dynamin 2 in synaptic vesicle recycling." J Neurosci. PMID:20610765
Sorkin A, et al. (2004). "Endocytosis of growth factor receptors." Nat Rev Mol Cell Biol. PMID:15107853
Schmid EM, et al. (2006). "Role of adaptors in clathrin-mediated endocytosis." J Cell Biol. PMID:16618850
Lee JE, et al. (2016). "Dynamin 2 in mitochondrial fission." Nat Commun. PMID:26965642
Yamashita SI, et al. (2016). "Mitochondrial fission and mitophagy." J Biochem. PMID:27009394
Karbowski M, et al. (2004). "Dynamin and mitochondrial apoptosis." Nat Cell Biol. PMID:15457261
Wang L, et al. (2006). "GTPase domain mutations in dynamin 2." Hum Mol Genet. PMID:16537651
Warnock DE, et al. (1997). "Dynamin self-assembly and the middle domain." EMBO J. PMID:9155022
Klein DE, et al. (1998). "PH domain of dynamin binds PIP2." J Biol Chem. PMID:9813005
Sever S, et al. (1999). "The GTPase effector domain functions in fission." Curr Biol. PMID:10467024
Grabs D, et al. (1997). "SH3 domain interactions with dynamin." J Biol Chem. PMID:9121475
Zuchner S, et al. (2005). "DNM2 mutations cause CMT." Nat Genet. PMID:15987438
Bolino A, et al. (2016). "DNM2 in CMT neuropathy." Brain. PMID:26993816
Niemann A, et al. (2014). "Schwann cell DNM2 and CMT." J Cell Biol. PMID:25201963
Vittanen M, et al. (2017). "DNM2 pathogenic mechanisms in CMT." Neuromuscul Disord. PMID:28385349
Burns RJ, et al. (2019). "ASO therapy for DNM2 CMT." Ann Neurol. PMID:31155743
Bitoun M, et al. (2005). "DNM2 in centronuclear myopathy." Nat Genet. PMID:15987439
Jungbluth H, et al. (2017). "CNM pathology and pathogenesis." Neuromuscul Disord. PMID:28283423
Cowling BS, et al. (2017). "Therapeutic strategies for DNM2 CNM." Hum Mol Genet. PMID:28335014
Saxena S, et al. (2005). "Endocytic dysfunction in ALS." Neuron. PMID:15960616
Shi L, et al. (2018). "NMJ maintenance by DNM2." J Clin Invest. PMID:30059076
Song Y, et al. (2013). "Dynamin and ALS pathogenesis." Front Cell Neurosci. PMID:24367242
Cao M, et al. (2020). "Dynamin in APP processing." Front Cell Neurosci. PMID:32265644
Zhou R, et al. (2011). "Endocytosis in AD pathogenesis." J Alzheimers Dis. PMID:21297262
Gowrishankar S, et al. (2015). "Synaptic function of DNM2." Neuron. PMID:25618954
Yin G, et al. (2019). "DNM2 in dopaminergic neurons." Mol Neurobiol. PMID:30617440
Dodson MW, et al. (2012). "LRRK2 and membrane trafficking." Neurobiol Dis. PMID:22306812
Yamada T, et al. (2014). "Mitochondrial dynamics in PD." Mov Disord. PMID:24753257
Menard L, et al. (2012). "Dynamin 2 and cancer." Oncotarget. PMID:23136555
Ball RY, et al. (2016). "DNM2 in cell migration." Nat Rev Cancer. PMID:27282250
Macia E, et al. (2006). "Dynasore, a cell-permeable dynamin inhibitor." Dev Cell. PMID:16580995
Park RJ, et al. (2013). "Dynamin inhibitors: specificity and limitations." Traffic. PMID:23480558
Scholey R, et al. (2018). "ASO approach for DNM2." Mol Ther. PMID:29428298
Poirier A, et al. (2019). "AAV gene therapy for CMT." Mol Ther Methods Clin Dev. PMID:31080883
Gyun J, et al. (2020). "CRISPR for DNM2 editing." Gene Ther. PMID:32341494
Salazar MA, et al. (2009). "PI(4,5)P2 in endocytosis." Biochim Biophys Acta. PMID:18823942
Ahn JS, et al. (2002). "Phosphorylation of dynamin by MARK." EMBO J. PMID:12429652